Matt Hoffman

Phase 3 data presented at ASH 2023 show the gene therapy significantly reduced annualized bleeding rates and the number of total bleeds.

The approval was based on evidence showing no clinically meaningful differences between natalizumab-sztn and the reference drug in terms of safety, purity, and potency.

Abbott's Proclaim XR spinal cord stimulation system allows patients with painful diabetic peripheral neuropathy to improve quality of life using a system that is easily incorporated into their everyday lives.

The past year has provided great steps forward in sleep science, and coupled with the lingering difficulties in care and the COVID-19 pandemic’s effects, the field is coming to a head to make sleep health a public health priority.

As the treatment paradigm for neurologic diseases rapidly progresses, the need for more thorough biomarker tools to measure disease progression and severity has increased. In recent years, GFAP has emerged as a valuable candidate to add to the existing panel.

The approval for Biogen’s disease-modifying, anti-amyloid agent aducanumab follows a long regulatory journey.

At the 76-week mark, reductions in the amyloid plaque level were 85.06 centiloids with donanemab than with placebo.

The Cassava Sciences agent showed 6-month improvements in both ADAS-Cog and NPI scores, and a phase 3 trial is expected to begin in late 2021.

After a sudden reversal and complex analyses, aducanumab’s future rests in the hands of the FDA while the community stands split on if the available data are enough to justify an approval.

The findings of this multicenter cohort may have implications for diagnosis, prognosis, and disease monitoring, as well as for clinical trials targeting disease-specific proteins in DLB.

History of syncope was present in 17% of the Parkinson group who had an altered blood pressure regulation upon standing and in 10% of those without.

Considerable discrepancy found between overt clinical symptoms of laryngeal pathology and abnormalities observed during a task protocol.

In a pair of studies, 42% of patients and care partners reported having no current treatment.

Three studies presented during the AAIC 2020 annual meeting show how frequent influenza vaccination help promote a gene-dependent reduction of Alzheimer disease by up to 40%.

New research finds a 13% higher mortality rate for every 5% reduction in REM sleep.

Patients who were treated with CLS-TA were able to achieve ≥3 lines of visual acuity 47% of the time, compared to 15% of the patients who received sham treatment.

Those who were switched to aflibercept improved 9 letters of VA, and 110 µm in CST from months 6 to 12.

After 6 months, 80% of those implanted with the 100 mg/mL dose of ranibizumab still did not need a medication refill.

The use of a single drop of nepafenac 0.3% suspension has shown in a trial to be an effective pain reducer post-intravitreal injection at both 6-hour and 24-hour points.

Amy S. Babicuh, MD, noted that “while DRIL is not the biomarker, it is certainly useful in conjunction with other information, and should prompt continued treatment with anti-VEGF agents when it is present.”

The modeled and lifetime QALY costs in the facility and out of the facility were $181,144 and $107,965, respectively, for PPV.

A population-based cohort study identified that patients with insomnia developed AMD at a rate 0.7% higher than those who did not.

The number of anti-VEGF injections patients underwent per 28 days decreased from 0.322 to 0.047 after FAc implantation.

The director of the Section of Uveitis and Vasculitis at Emory University spoke about the potential of this novel delivery method in conditions such as uveitis and retinal vein occlusion.

The treatment, traditionally used for cancer, not only improved BVCA measurements but also resulted in the number of injections patients needed.

At the final follow-up in year 5, 16.5% of eyes had lost >15 ETDRS letters, compared to 33% that had gained >15 ETDRS letters.

The analysis suggests that patients with neovascular AMD may be undertreated in clinical practice settings.

An examination of trials supporting the 46 therapies approved via the Breakthrough Therapy designation has shown that fewer data supports their approval than what may be believed.

A few months after performing a first-of-its-kind procedure in the US, members of the John Ochsner Heart and Vascular Institute surgical team explore what led to the surgical success.

Only 3.03% of the SPI group reported suicidal behaviors, compared to 5.29% of those receiving usual care during the 6-month follow-up period.